GLP-1 Litigation Tracker (May 2026): MDL 3094 Hits 3,636 GI Cases + MDL 3163 Reaches 86 NAION Vision-Loss Cases Before Judge Marston (E.D. Pa.)
Two federal multidistrict litigations against GLP-1 manufacturers continue to expand. MDL 3094 — In Re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation — now consolidates 3,636 cases alleging gastrointestinal injury, including gastroparesis and severe vomiting. MDL 3163, created December 15, 2025 after the JPML approved consolidation of vision-loss cases tied to non-arteritic anterior ischemic optic neuropathy (NAION), holds 86 cases as of May 6. Both sit before Judge Karen S. Marston in the Eastern District of Pennsylvania; no bellwether trial has been scheduled and no global settlement is in negotiation.